EUVIMEDScopri EUVIMED
Crossref

Targeted therapy using larotrectinib and venetoclax for the relapsed/refractory T‐cell acute lymphoblastic leukemia harboring a cryptic ETV6‐NTRK3 fusion

Kuangguo Zhou iD, Duanhao Gong, Cheng He, Min Xiao, Meilan Zhang, Wei Huang

Molecular Carcinogenesis · 2023

DOI: 10.1002/mc.23534 ↗

At a glance

Journal article in Molecular Carcinogenesis, 2023. Written by Kuangguo Zhou and 5 co-authors. Institution: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Major MEDLINE topics: Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Cited 4 times so far (Crossref); 33 references. Funded by: National Natural Science Foundation of China.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Outcomes for patients with relapsed and refractory (R/R) T‐cell acute lymphoblastic leukemia (T‐ALL) after allogeneic hematopoietic stem cell transplantation (allo‐HSCT) are dismal, with few available treatments. Recently, identification of cancer patients harboring neurotrophic tropomyosin receptor kinase (NTRK) gene fusions is constantly increasing, especially with the advent of NTRK inhibitors. However, the role of ETV6‐NTRK3 in T‐ALL has not been investigated. This case represented the first detailed report of T‐ALL patient harboring a cryptic ETV6‐NTRK3 fusion with an unfavorable prognosis, not only because of leukemia resistant to the standard multiagent chemotherapy but also early relapse after allo‐HSCT. Acquired EP300 mutation was found at relapse, which could explain the cause of recurrence and affect the follow‐up treatment. Combined targeted therapy like larotrectinib allied with pan‐targeted BCL‐2 inhibitor venetoclax, may be a potential maintenance treatment in R/R ETV6‐NTRK3 positive leukemia after allo‐HSCT. The leukemic clonal evolution might be revealed through transcriptome sequencing and overcome by drugs with universal targets. Our case demonstrated that both comprehensive profiling techniques (such as transcriptome sequencing, multiparameter flow cytometry, and digital droplet polymerase chain reaction) and a multimodality treatment strategy were critical for anticipating an early relapse and personalized therapy of R/R T‐cell leukemia.

Subjects

MeSH terms (MEDLINE)

Precursor T-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaHumansRecurrenceT-LymphocytesOncogene Proteins, FusionPyrazolesPyrimidinesSulfonamidesBridged Bicyclo Compounds, HeterocyclicReceptor, trkCETS Translocation Variant 6 Protein

Author keywords

ETV6-NTRK3T-cell acute lymphoblastic leukemialarotrectinibtargeted therapyvenetoclax

Substances

Oncogene Proteins, FusionlarotrectinibPyrazolesPyrimidinesvenetoclaxSulfonamidesBridged Bicyclo Compounds, HeterocyclicETV6-NTRK3 fusion protein, humanReceptor, trkCETS Translocation Variant 6 Protein

Authors and institutions

  • Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

ORCID profiles: Kuangguo Zhou

Funding

  • National Natural Science Foundation of China

Cite

APA

Zhou, K., Gong, D., He, C., Xiao, M., Zhang, M., & Huang, W. (2023). Targeted therapy using larotrectinib and venetoclax for the relapsed/refractory T‐cell acute lymphoblastic leukemia harboring a cryptic ETV6‐NTRK3 fusion. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23534

Vancouver

Zhou K, Gong D, He C, Xiao M, Zhang M, Huang W. Targeted therapy using larotrectinib and venetoclax for the relapsed/refractory T‐cell acute lymphoblastic leukemia harboring a cryptic ETV6‐NTRK3 fusion. Molecular Carcinogenesis. 2023. doi:10.1002/mc.23534

BibTeX
@article{Zhou2023,
  author = {Zhou, Kuangguo and Gong, Duanhao and He, Cheng and Xiao, Min and Zhang, Meilan and Huang, Wei},
  title = {Targeted therapy using larotrectinib and venetoclax for the relapsed/refractory T‐cell acute lymphoblastic leukemia harboring a cryptic ETV6‐NTRK3 fusion},
  journal = {Molecular Carcinogenesis},
  year = {2023},
  doi = {10.1002/mc.23534}
}
Start for free →